NCT02171988

Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)

Comparison of Effect of Propranolol, Bisoprolol, Pyridosgitmine in Postural Orthostatic Tachycardia Syndrome (POTS) and Prognosis After Medical Treatment

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 15 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to investigate effect of medical treatment and prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)

Detailed description

Many patients who complained of dizziness are eventually diagnosed as POTS. However, the investigation of an appropriate medical treatment of POTS has not been enough yet. Also, the prognosis of the disease after treatment is not well known. It is known that propranolol attenuate the tachycardia and improve symptom burden in patients with POTS. However, the effect of other β-Blocker, bisoprolol compared with propranolol is not known well. In addition, acetylcholinesterase inhibition with pyridostigmine was a effective method of acutely decreasing the tachycardia in patients with POTS. However, difference among three medical treatments effect is not known and long-term studies are not done yet. Therefore, in this study investigator investigate effect of medical treatment (propranolol only, bisoprolol only, propranolol+pyridostigmine, bisoprolol+pyridostigmine) and prognosis of Postural Orthostatic Tachycardia Syndrome. Longer-term studies are needed to assess this promising therapy.

Conditions

• Postural Orthostatic Tachycardia Syndrome

Interventions

Type	Name	Description
DRUG	Propranolol	Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
DRUG	Bisoprolol	Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
DRUG	Propranolol+pyridostigmine	Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
DRUG	Bisoprolol+pyridostgmine	Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable

Timeline

• Start date: 2014-03-01
• Primary completion: 2016-02-01
• Completion: 2016-12-01
• First posted: 2014-06-24
• Last updated: 2018-04-18

Locations

1 site across 1 country: South Korea